VAX-31’s safety, tolerability, and immunogenicity are being assessed in this trial on healthy infants. Vaxcyte anticipat ...

Vaxcyte (PCVX) announced that the first study participants have been dosed in the second and final stage of the ongoing Phase 2 study of VAX-31 ...

Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data -- -- Company Expects to ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that Capvaxive be used to prevent invasive disease ...

The Ministry of Health (MoH) has introduced the pneumococcal conjugate vaccine (PCV) into Brunei Darussalam’s Expanded Programme on Immunisation, effective FeB 1 as part of efforts to protect infants ...

The U.S. Senate Finance Committee could vote as soon as Tuesday on Robert F. Kennedy Jr.’s controversial nomination to be ...

What you need to know ### BMJ Learning To obtain accredited continuous professional development points, subscribers to BMJ Learning can complete the full module at The module contains seven ...

Merck receives positive EU CHMP opinion for Capvaxive for pneumococcal vaccination in adults: Rahway, New Jersey Monday, February 3, 2025, 12:00 Hrs [IST] Merck, known as MSD outs ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ...

What are the current CDC recommendations for vaccines? Here's the list from the government website as of Jan. 30, 2025.

The PCV was well tolerated. Conclusion: The pneumococcal antibody concentrations at 13 months were comparable with those noted previously with the 4-dose schedule. The results suggest that the ...

The pharmacist confirms the patient's risk of pneumococcal disease ... are the vaccination rate and the percentage of omitted doses. The pharmacy department assumed the responsibility for ongoing ...